Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2023

Open Access 01-12-2023 | Research

RNA-seq reveals novel mechanistic targets of Livin in bladder cancer

Authors: Xianwen Li, Chunhua Fu, Guofeng Li, Haolin He

Published in: BMC Urology | Issue 1/2023

Login to get access

Abstract

Background

Bladder cancer is a very common malignancy with a high recurrence rate. The survival of patients with muscle-invasive bladder cancer is poor, and new therapies are needed. Livin has been reported to be upregulated in bladder cancer and influence the proliferation of cancer cells.

Materials and methods

The Livin gene in human bladder cancer cell line T24 was knocked out, and the differentially expressed genes were identified by RNA-seq and qPCR.

Results

Livin knockdown affects gene expression and has strong negative effects on some cancer-promoting pathways. Furthermore, combined with bladder cancer clinical sample data downloaded from TCGA and GEO, 2 co-up-regulated genes and 58 co-down-regulated genes were identified and validated, which were associated with cancer proliferation and invasion.

Conclusion

All these results suggest that Livin plays an important role in bladder cancer and could be a potential anticancer target in clinical therapy.
Appendix
Available only for authorised users
Literature
1.
van Kessel KE, Zuiverloon TC, Alberts AR, et al. Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol. 2015;12(12):681–94.CrossRefPubMed
2.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
3.
Garg M. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev. 2015;34(4):691–701.CrossRefPubMed
4.
5.
DeVita VT Jr, Chu E. A history of cancer chemotherapy. Can Res. 2008;68(21):8643–53.CrossRef
6.
Rebouissou S, Bernard-Pierrot I, de Reyniès A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6(244):244ra91.CrossRefPubMed
7.
Wu CL, Ping SY, Yu CP, et al. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J Med Sci. 2012;28(4):194–203.CrossRefPubMed
8.
Ge Y, Liu BL, Cui JP, et al. Livin promotes colon cancer progression by regulation of H2A.XY39ph via JMJD6. Life Sci. 2019;234:116788.CrossRefPubMed
9.
Liu C, Wu X, Luo C, et al. Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3. J Exp Clin Cancer Res. 2010;29(1):63.CrossRefPubMed
10.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinform (Oxford, England). 2010;26(1):139–40.
11.
Rajkumar AP, Qvist P, Lazarus R, et al. Experimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq. BMC Genomics. 2015;16(1):548.CrossRefPubMedPubMedCentral
12.
Alexa A, Rahnenfuhrer J. topGO: enrichment analysis for gene ontology. R Packag Version. 2010;2:2010.
13.
14.
15.
Liu HB, Kong CZ, Zeng Y, et al. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol. 2009;27(3):277–83.CrossRefPubMed
16.
Yang D, Song X, Zhang J, et al. Suppression of livin gene expression by siRNA leads to growth inhibition and apoptosis induction in human bladder cancer T24 cells. Biosci Biotechnol Biochem. 2010;74(5):1039–44.CrossRefPubMed
17.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
18.
Kang XL, Geng ZH, Lu XX, et al. Detecting multi-drug resistance of bladder cancer for the intravesical chemotherapy. Zhonghua Wai Ke Za Zhi. 2004;42(5):285–7.PubMed
19.
Miyake M, Ishii M, Koyama N, et al. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther. 2010;332(3):795–802.CrossRefPubMed
20.
21.
Herrera-Abreu MT, Pearson A, Campbell J, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013;3(9):1058–71.CrossRefPubMedPubMedCentral
22.
Bhuvaneswari R, Gan YY, Soo KC, et al. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer. 2009;8:94.CrossRefPubMedPubMedCentral
23.
Augello C, Caruso L, Maggioni M, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125.CrossRefPubMedPubMedCentral
24.
Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol Off J Eur Soc Med Oncol. 2003;14(1):85–90.CrossRef
25.
Wang J, Zhang X, Wei P, et al. Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer. World J Urol. 2014;32(6):1477–84.CrossRefPubMed
26.
Zhou D, Tang W, Zhang Y, et al. JAM3 functions as a novel tumor suppressor and is inactivated by DNA methylation in colorectal cancer. Cancer Manag Res. 2019;11:2457–70.CrossRefPubMedPubMedCentral
27.
Okumura F, Fujiki Y, Oki N, et al. Cul5-type ubiquitin ligase KLHDC1 contributes to the elimination of truncated SELENOS produced by failed UGA/Sec decoding. Science. 2020;23(3):100970.
28.
Chakraborty S, Lakshmanan M, Swa HL, et al. An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat Commun. 2015;6:6184.CrossRefPubMed
29.
Tian C, Öhlund D, Rickelt S, et al. Cancer cell-derived matrisome proteins promote metastasis in pancreatic ductal adenocarcinoma. Cancer Res. 2020;80(7):1461–1474.CrossRefPubMedPubMedCentral
30.
Li X, Wang X, Song W, et al. Oncogenic properties of NEAT1 in prostate cancer cells depend on the CDC5L-AGRN transcriptional regulation circuit. Cancer Res. 2018;78(15):4138–49.CrossRefPubMed
31.
Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009;101(7):519–32.CrossRefPubMedPubMedCentral
32.
Bastos DC, Ribeiro CF, Ahearn T, et al. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. J Pathol. 2021;253(3):292–303.CrossRefPubMed
33.
Liu Z, Sun Q, Wang X. PLK1, a potential target for cancer therapy. Transl Oncol. 2017;10(1):22–32.CrossRefPubMed
34.
35.
36.
Fan X, Wang Y. B-Myb accelerates colorectal cancer progression through reciprocal feed-forward transactivation of E2F2. Oncogene. 2021;40(37):5613–25.CrossRefPubMedPubMedCentral
37.
Metadata
Title
RNA-seq reveals novel mechanistic targets of Livin in bladder cancer
Authors
Xianwen Li
Chunhua Fu
Guofeng Li
Haolin He
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2023
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-023-01194-w

Other articles of this Issue 1/2023

BMC Urology 1/2023 Go to the issue

Research

Serum creatinine trajectory after drainage of kidneys with bilateral malignant ureteral obstruction: a prospective non-randomized comparative study

Research

De-epithelialized overlap flap to secure urethroplasty in second stage hypospadias repair: revisiting the Smith technique

Research

A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

Case report

Robotic partial cystectomy with excision of mesh after inguinal hernia repair: a case report

Case report

An abrupt decrease in arterial blood pressure may predict a high level carbon dioxide embolism in retroperitoneoscopic surgery: case report and a literature review

Research

Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer